COVID-19 Infection in Egyptian Older Patients: Does it Differ?
Ahmed F Sherief1, Rana M Taha2*, Hany M Dabbous1, Maha Elgaafary3, Ahmed T Elganzory1, Mahmoud M Mahmoud4, Amal MI Goda3 and Mohamed M Eltabbakh1
1Tropical Medicine Department, Faculty of Medicine, Ain Shams University, Cairo, Egypt
2Geriatrics Medicine and Gerontology Department, Faculty of Medicine, Ain Shams University, Cairo, Egypt
3Department of Community, Environmental and Occupational Medicine, Faculty of Medicine, Ain Shams University, Cairo, Egypt
4Department of Chest Diseases, Faculty of Medicine, Ain Shams University, Cairo, Egypt
*Corresponding Author: Rana M Taha, Lecturer of Geriatrics Medicine and Gerontology, Faculty of Medicine, Ain Shams University, Cairo, Egypt.
Received: June 08, 2021 ; Published: July 16, 2021
The affection of older population was noticed early in COVID-19 pandemic with a less favorable outcome. Differences in mortality and prevalence were observed between countries, which could be explained by various theories. We conducted this study to investigate and compare the clinical characteristics of COVID-19 among elderly with young and middle-aged patients. Descriptive comparative study was conducted on 139 confirmed COVID-19 cases recruited from Ain Shams University Specialized Hospital in Obour City from May 1st to June 15th, 2020. According to age, cases were divided into two groups: the elderly group (≥ 60 years old), with 66 patients, and the middle-aged group (< 60 years old), with 73 patients. The mean age of elderly group was 66 years, while that of young and middle-aged group was 38 years. Besides, the elderly group demonstrated higher CURB65 score than that of young and middle-aged group (P < 0.01). In older patients, development of acute respiratory distress syndrome (ARDS) and septic shock was significantly higher than that of young and middle-aged patients. Furthermore, older patients group exhibited significantly higher mortality than the other group, reaching 13 (19.7%) and 3 (4.1%), respectively. The older population remains the most vulnerable group, suffering from significant morbidity and mortality during COVID-19 pandemic.
Keywords: COVID-19; Older Patients; CURB65; ARDS; Mortality
- Zhu N., et al. “A novel coronavirus from patients with pneumonia in China, 2019”. The New England Journal of Medicine 8 (2020): 727-733.
- World Health Organization. “WHO Coronavirus Disease (COVID-19) Dashboard” (2021).
- Centers for Disease Control and Prevention. “Coronavirus Disease 2019 (COVID-19)” (2020).
- “Ministry of health and population” (2021).
- Shi Y., et al. “An overview of COVID-19”. Journal of Zhejiang University Science B 5 (2020): 343-360.
- Boccardi V., et al. “COVID-19: A Geriatric Emergency”. Geriatrics (Basel)2 (2020): E24.
- Perrotta F., et al. “COVID-19 and the elderly: insights into pathogenesis and clinical decision-making”. Aging Clinical and Experimental Research8 (2020): 1599-1608.
- Lim WS., et al. “Defining community acquired pneumonia severity on presentation to hospital: an international derivation and validation study”. Thorax5 (2003): 377-382.
- “British Society of thoracic imaging” (2020).
- Schoeman D and Fielding BC. “Coronavirus envelope protein: current knowledge”. Virology Journal1 (2019): 69.
- Channappanavar R., et al. “Sex-based differences in susceptibility to severe acute respiratory syndrome coronavirus infection”. Journal of Immunology 198 (2017): 4046-4053.
- Chen N., et al. “Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study”. Lancet10223 (2020): 507-513.
- Liu K., et al. “Clinical features of COVID-19 in elderly patients: a comparison with young and middle-aged patients”. Journal of Infection (2020).
- Assiri A., et al. “Epidemiological, demographic, and clinical characteristics of 47 cases of Middle East respiratory syndrome coronavirus disease from Saudi Arabia: a descriptive study”. Lancet Infectious Disease 13 (2013): 752-761.
- Wang L., et al. “Coronavirus disease 2019 in elderly patients: Characteristics and prognostic factors based on 4-week follow-up”. Journal of Infection6 (2020): 639-645.
- Meftahi GH., et al. “The possible pathophysiology mechanism of cytokine storm in elderly adults with COVID-19 infection: the contribution of "inflame-aging". Inflammatory Research9 (2020): 825-839.
- Lekamwasam R and Lekamwasam S. “Effects of COVID-19 Pandemic on Health and Wellbeing of Older People: A Comprehensive Review”. Annals of Geriatric Medicine and Research 3 (2020): 166-172.
- Rinaldi L., et al. “Relevance of lung ultrasound in the diagnostic algorithm of respiratory diseases in a real-life setting: a multicentre prospective study”. Respirology (2019).
- Bellani G., et al. “Epidemiology, patterns of care, and mortality for patients with acute respiratory distress syndrome in intensive care units in 50 countries”. JAMA8 (2016): 788-800.
- Sanders JM., et al. “Pharmacologic Treatments for Coronavirus Disease 2019 (COVID-19): A Review”. JAMA 18 (2020): 1824-1836.
- Du YX and Chen XP. “Favipiravir: Pharmacokinetics and Concerns About Clinical Trials for 2019‐nCoV Infection”. Clinical Pharmacology Therapy 108 (2020): 242-247.
- Guaraldi G., et al. “Tocilizumab in patients with severe COVID-19: a retrospective cohort study”. Lancet Rheumatology8 (2020): e474-e484.
- Liu W., et al. “Analysis of factors associated with disease outcomes in hospitalized patients with 2019 novel coronavirus disease”. Chinese Medical Journal (Engl).9 (2020): 1032-1038.